Go Back to Match Results for ""
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)
Study Overview
This randomized phase III clinical trial compares how well combination chemotherapy works when given with or without bortezomib in treating patients with newly diagnosed T-cell acute lymphoblastic leukemia or stage II-IV T-cell lymphoblastic lymphoma.
Study Description
This randomized phase III clinical trial compares how well combination chemotherapy works when given with or without bortezomib in treating patients with newly diagnosed T-cell acute lymphoblastic leukemia or stage II-IV T-cell lymphoblastic lymphoma.
Additional Information
- IRB Number: 1410336909 (PHO-COG-FALLON-AALL1231)
- Research Study Identifier: TX4390
- Principal Investigator: Robert Fallon, MD
Recruitment Status
OpenContact the research team to learn more about this study.
Fields marked with asterisk (*) are required
